9 news items
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
ANNX
17 Jun 24
candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data
Annexon Announces Pricing of $125 Million Underwritten Public Offering
ANNX
5 Jun 24
meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré syndrome
Annexon Announces Proposed Public Offering of Common Stock
ANNX
4 Jun 24
candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
ANNX
3 Jun 24
before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
ANNX
16 May 24
candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data
jbuc118gmcqik4lxh398w tpo
ANNX
7 May 24
functional benefit for millions of patients. We look forward to advancing ANX007 into registrational Phase 3 trials in GA expected to initiate by mid
p0uhvy54lbn8tqxv7uzfa7ej7d8hk1anxmbf0rgoq3789n7yw3e7
ANNX
1 May 24
offer a major therapeutic advantage over existing treatments or benefit to patients without treatment options. In the randomized, multi
qkgq73s7otaiyekcx02m6urdg5r53i1twfs
ANNX
16 Apr 24
are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data
smqk7yvc ttripzd7ruw95u1rgyy4423j98zc6q2
ANNX
26 Mar 24
it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases
- Prev
- 1
- Next